Intestinal mucin glycotope

Intestinal mucin glycotopes are specific carbohydrate motifs found on the O-glycan chains of mucin proteins, such as MUC2, which are densely packed in the intestinal epithelium. These glycotopes serve as critical components of the mucosal barrier, mediating interactions with the gut microbiota and protecting the underlying tissue from enzymatic and physical damage [1][2]. In diseases such as colorectal cancer and ulcerative colitis, the normal glycosylation process is altered, leading to the presentation of truncated or hypersialylated glycotopes known as tumor-associated carbohydrate antigens (TACAs) [3]. These aberrant structures, including the Tn, sialyl-Tn (STn), and Thomsen-Friedenreich (TF) antigens, are highly specific to malignant or inflamed tissues, making them attractive targets for precision medicine [4]. Therapeutic approaches include the development of monoclonal antibodies, such as gatipotuzumab, and carbohydrate-based vaccines like MAG-Tn3, which aim to trigger an immune response against cells expressing these pathological glycotopes [5]. Despite their potential, challenges remain regarding the low immunogenicity of glycans and the need for high specificity to avoid off-target effects on healthy mucosal surfaces [6].

Other names

Mucin-type O-glycanTumor-associated carbohydrate antigenTACAMucin glycan epitopeIntestinal O-linked glycan

Targeting of truncated O-glycans via monoclonal antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) and utilization of glycan-conjugate vaccines to stimulate anti-tumor immunity.